Clinical Trial Update: Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating shorter-duration androgen receptor pathway inhibitor therapy with apalutamide and enzalutamide for patients with low-volume metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Xtandi (enzalutamide)

Snippet

Sponsor: Nick Beije | Conditions: Prostate Cancer | Phase 3 | Status: RECRUITING